DERMATOLOGY

Phase 3:

JADE EXTEND PF-04965842 is an investigational JAK1 inhibitor for atopic dermatitis1,2

PDF icon Download (1.34 MB)
Phase 3:

JADE TEEN PF-04965842 is an investigational JAK1 inhibitor for atopic dermatitis1,3

PDF icon Download (1.33 MB)
Phase 3:

JADE COMPARE PF-04965842 is an investigational JAK1 inhibitor for atopic dermatitis1,4

PDF icon Download (1.35 MB)
Phase 3:

JADE REGIMEN PF-04965842 is an investigational JAK1 inhibitor for atopic dermatitis1,5

PDF icon Download (1.31 MB)
Phase 2b/3:

PF-06651600 is an investigational oral JAK3/TEC inhibitor for alopecia areata6,7,17

PDF icon Download (1.29 MB)
Phase 2b:

PF-06700841 is an investigational oral TYK2/JAK1 inhibitor and
PF-06651600 is an investigational oral JAK3/TEC inhibitor for non-segmental vitiligo8,17

PDF icon Download (1.32 MB)
Phase 2b:

PF-06700841 is an investigational topical TYK2/JAK1 inhibitor for plaque psoraisis9

PDF icon Download (1.25 MB)
Phase 2:

PF-06826647 is an investigational oral TYK2 inhibitor for plaque psoraisis11

PDF icon Download (1.25 MB)
Phase 2:

PF-06700841 is an investigational topical TYK2/JAK1 inhibitor for atopic dermetitis10

PDF icon Download (1.27 MB)

GASTROENTEROLOGY

Phase 2:

PF-06687234 is an investigational IL-10 agonist for ulcerative colitis12

PDF icon Download (1.3 MB)
Phase 2:

PF-06700841 is an investigational oral TYK2/JAK1 inhibitor and PF-06651600
is an investigational oral JAK3/TEC inhibitor for ulcerative colitis13,17

PDF icon Download (1.34 MB)
Phase 2:

PF-06700841 is an investigational oral TYK2/JAK1 inhibitor and PF-06651600
is an investigational oral JAK3/TEC inhibitor for Crohn's disease14,17

PDF icon Download (1.36 MB)

RHEUMATOLOGY

Phase 2b:

PF-06700841 is an investigational oral TYK2/JAK1 inhibitor for lupus15

PDF icon Download (1.25 MB)
Phase 2b:

PF-06700841 is an investigational oral TYK2/JAK1 inhibitor for psoriatic arthritis16

PDF icon Download (1.24 MB)